About
Technology
Issues
FAQ
Links
Official Page
Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.